Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Clearside Biomedical ( (CLSD) ) is now available.
On September 10, 2025, Clearside Biomedical, Inc. filed a Certificate of Amendment to implement a one-for-fifteen reverse stock split and reduce the total number of authorized shares from 400,000,000 to 26,666,666, effective September 12, 2025. This move, approved by stockholders and the board, aims to adjust the company’s stock structure, affecting all outstanding shares and stock options proportionately, with trading on a split-adjusted basis beginning September 15, 2025.
The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.
Clearside Biomedical faces significant financial challenges, with declining revenues and negative equity being the most impactful factors. The technical analysis indicates a bearish trend, and valuation metrics are poor. While recent corporate events provide some positive aspects, the overall outlook remains risky.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. operates in the biotechnology industry, focusing on developing therapies to treat eye diseases. The company specializes in delivering drugs to the back of the eye using its proprietary SCS Microinjector technology.
Average Trading Volume: 4,521,309
Technical Sentiment Signal: Sell
Current Market Cap: $26.06M
Learn more about CLSD stock on TipRanks’ Stock Analysis page.